Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Bruker Corp.
Headquarters: Billerica, MA, United States of America
Website: http://www.bruker.com
Year Founded: 1991
Status: Public
Industry Sector: HealthTechnology
CEO: Frank H. Laukien, PhD
Number Of Employees: 11,396
Enterprise Value: $10,859,590,000
PE Ratio: 62.08
Exchange/Ticker 1: NASDAQ:BRKR
Exchange/Ticker 2: N/A
Latest Market Cap: $7,151,373,312
BioCentury | Apr 23, 2024
Deals
Deals report: Two Japanese pharmas set up local biotech incubator
Plus: Takeda licenses immuno-oncology program from Kumquat, and deals for Ipsen-Skyhawk, Boehringer-Ochre and more
BioCentury | Dec 13, 2023
Finance
Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M
Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more
BioCentury | Feb 11, 2023
Emerging Company Profile
Haystack: personalized liquid biopsy tests for minimal residual disease
Baltimore biotech readies to launch colon cancer monitoring test, funded by $56M series A led by co-founder Catalio
BioCentury | Sep 17, 2020
Product Development
Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies
Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT)
BioCentury | Mar 25, 2020
Product Development
Bruker-Novacyt, PerkinElmer launch COVID-19 diagnostics; plus Nuclein speeds development its PCR test
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Items per page:
1 - 10 of 28